Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trialSamir K. Gupta, Ellen Koenig, Moti Ramgopal et al.|The Lancet HIV|2022Cited by 107
Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cellsBrian L. Robbins, Arnold Fridland, Jack Rodman et al.|Antimicrobial Agents and Chemotherapy|1994Cited by 68